GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
Renalyx will continue operating as an independent unit within the group
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Owlet’s push comes as parents demand smarter, more dependable nursery tech
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Subscribe To Our Newsletter & Stay Updated
